[go: up one dir, main page]

DK1123093T3 - Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det - Google Patents

Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det

Info

Publication number
DK1123093T3
DK1123093T3 DK99954343T DK99954343T DK1123093T3 DK 1123093 T3 DK1123093 T3 DK 1123093T3 DK 99954343 T DK99954343 T DK 99954343T DK 99954343 T DK99954343 T DK 99954343T DK 1123093 T3 DK1123093 T3 DK 1123093T3
Authority
DK
Denmark
Prior art keywords
intramitochondrial
ubiquinones
ubiquinone
transport
methods
Prior art date
Application number
DK99954343T
Other languages
Danish (da)
English (en)
Inventor
Janos Feher
Grazia Sears
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11343466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1123093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Application granted granted Critical
Publication of DK1123093T3 publication Critical patent/DK1123093T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
DK99954343T 1998-10-21 1999-10-19 Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det DK1123093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998BO000596A IT1304406B1 (it) 1998-10-21 1998-10-21 Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
PCT/IT1999/000331 WO2000023069A1 (fr) 1998-10-21 1999-10-19 Composition renfermant de l'ubiquinone destinee a favoriser le transport intramitochondrial des ubiquinones, et procede d'utilisation de cette composition

Publications (1)

Publication Number Publication Date
DK1123093T3 true DK1123093T3 (da) 2003-08-11

Family

ID=11343466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99954343T DK1123093T3 (da) 1998-10-21 1999-10-19 Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det

Country Status (11)

Country Link
US (1) US6417233B1 (fr)
EP (1) EP1123093B1 (fr)
AR (1) AR023338A1 (fr)
AT (1) ATE237323T1 (fr)
AU (1) AU1074600A (fr)
DE (1) DE69907010T2 (fr)
DK (1) DK1123093T3 (fr)
ES (1) ES2196874T3 (fr)
IT (1) IT1304406B1 (fr)
PT (1) PT1123093E (fr)
WO (1) WO2000023069A1 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307281B1 (it) * 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
EP1249230B1 (fr) * 2001-04-12 2003-11-05 Vesifact Ag Microémulsions et préconcentrés en microémulsion comprenant de la coenzyme Q10
US6582723B2 (en) * 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP4603192B2 (ja) * 2001-05-10 2010-12-22 株式会社カネカ 毛髪頭皮用組成物
MXPA03010888A (es) * 2001-05-30 2004-02-27 Laxdale Ltd Coenzimas q y acido eicosapentaenoico (epa).
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
ITRM20010755A1 (it) * 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
TW200302056A (en) * 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
CA2471821C (fr) * 2002-11-04 2006-04-25 Ocean Nutrition Canada Limited Microcapsules presentant plusieurs enveloppes et procede de fabrication de celles-ci
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
US7875291B1 (en) 2003-09-05 2011-01-25 Glu-Pro, Inc. Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
CN1909895A (zh) * 2004-01-08 2007-02-07 株式会社钟化 抗衰老组合物
ES2631152T3 (es) 2004-01-22 2017-08-28 University Of Miami Formulaciones de coenzima Q10 tópicas o intravenosas para su uso en el tratamiento del cáncer
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
DE102004041270A1 (de) * 2004-08-26 2006-03-02 Merz Pharma Gmbh & Co. Kgaa Ein Kapillar- Wirksystem enthaltende Zusammensetzungen mit anwendungsbezogener Differenzierbarkeit und deren Verwendung
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
DE602006011127D1 (de) * 2005-01-27 2010-01-28 Ocean Nutrition Canada Ltd Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
WO2006109194A2 (fr) * 2005-01-27 2006-10-19 Ocean Nutrition Canada Ltd. Composes de chrome et d'acides gras et leurs procedes de fabrication et d'utilisation
EP2564843B1 (fr) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Produits thérapeutiques actifs en réduction-oxydation destines au traitement de maladies mitochondriales et d'autres états ainsi que la modulation de bio-marqueurs d'énergie
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
LT1933821T (lt) * 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
WO2007061752A2 (fr) * 2005-11-17 2007-05-31 Bioavailability, Inc. Emulsifiants latents biocompatibles
CA2634139C (fr) * 2005-12-20 2015-06-23 Cenestra, Llc. Preparations a base d'acide gras omega 3
US20070184041A1 (en) * 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
EP1986636B1 (fr) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Derives du phenol et de la 1,4-benzoquinone pour leur utilisation dans le traitement des maladies mitochondriales
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
CA2643662A1 (fr) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions et microcapsules contenant des substances a faible tension interfaciale, leurs procedes de fabrication et d'utilisation
US8491888B2 (en) * 2006-05-05 2013-07-23 Softgel Formulators, Inc. Highly absorbable coenzyme Q10 composition and method of producing same
PL2040682T3 (pl) * 2006-06-05 2018-01-31 Dsm Nutritional Products Ag Mikrokapsułki o ulepszonych otoczkach
KR100801057B1 (ko) * 2006-07-18 2008-02-04 삼성전자주식회사 컬러 보정 블럭을 구비하는 ｃｍｏｓ 이미지 센서 및 그이미지 센싱 방법
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
KR101430214B1 (ko) * 2006-12-28 2014-08-18 산토리 홀딩스 가부시키가이샤 신경 재생제
AU2008205325B2 (en) 2007-01-10 2013-09-12 Dsm Nutritional Products Ag Vegetarian microcapsules
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
KR100943652B1 (ko) * 2007-12-28 2010-02-25 (주)미토콘 생체이용율이 향상된 코엔자임큐10 함유 조성물
EP2271325A4 (fr) 2008-04-11 2011-11-09 Cytotech Labs Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010111397A1 (fr) * 2009-03-24 2010-09-30 Adds Pharmaceuticals Llc Formulations stabilisées à solubilité accrue pour administration par voie orale
US10519504B2 (en) * 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2010313249B2 (en) * 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
US11400058B2 (en) * 2010-03-12 2022-08-02 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
EP2694463B8 (fr) 2011-04-04 2019-10-09 Berg LLC Traitement de tumeurs du système nerveux central avec coenzyme q10
CA2834342C (fr) 2011-04-26 2021-08-31 Retrotope, Inc. Troubles de traitement compromis de l'energie et deficiences mitochondriales
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
DK2701697T3 (da) 2011-04-26 2020-06-29 Retrotope Inc Oxidative nethindesygdomme
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
AU2014285095A1 (en) * 2013-07-03 2016-02-25 Barrie Tan CoQ10 (ubiquinone, ubiquinol), vitamin A (retinoic acid, retinol), vitamin E (tocotrienol, tocopherol) and methods of use
WO2015035094A1 (fr) 2013-09-04 2015-03-12 Berg Llc Procédés de traitement du cancer par perfusion continue de coenzyme q10
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
WO2017087576A1 (fr) 2015-11-16 2017-05-26 Berg Llc Procédés de traitement de gliome résistant au témozolomide utilisant la coenzyme q10
EP3950649A1 (fr) 2015-11-23 2022-02-09 Retrotope, Inc. Marquage isotopique spécifique de site de systèmes 1,4-diènes
DE202015106479U1 (de) 2015-11-29 2016-03-09 Cathleen Straßburger Stapelhilfe und Abdeckhaube für den Transport von Cateringmaterial zum Kunden
WO2017106803A1 (fr) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Dérivés fluoroalkyle, fluoroalcoxy, phénoxy, hétéroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
KR20220143931A (ko) 2020-02-21 2022-10-25 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JP2643217B2 (ja) 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
NO304009B1 (no) 1997-02-04 1998-10-12 Gunnar Volden Hudpreparat
CA2260397A1 (fr) * 1999-01-29 2000-07-29 Atlantis Marine Inc. Methode pour convertir l'huile fondue de triglyceride provenant de sources marines en huile alimentaire douce et stable

Also Published As

Publication number Publication date
ITBO980596A0 (it) 1998-10-21
ITBO980596A1 (it) 2000-04-21
US6417233B1 (en) 2002-07-09
WO2000023069A1 (fr) 2000-04-27
AR023338A1 (es) 2002-09-04
PT1123093E (pt) 2003-09-30
EP1123093B1 (fr) 2003-04-16
DE69907010T2 (de) 2004-02-19
DE69907010D1 (de) 2003-05-22
IT1304406B1 (it) 2001-03-19
ES2196874T3 (es) 2003-12-16
AU1074600A (en) 2000-05-08
EP1123093A1 (fr) 2001-08-16
ATE237323T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DK1123093T3 (da) Ubiquinonholdig sammensætning egnet til at fremme øget intramitochondrisk transport af ubiquinoner og fremgangsmåder til at anvende det
DK1220849T3 (da) Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf
DK1339292T3 (da) Sammensætning og fremgangsmåde
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
NO991151D0 (no) Forbindelse og anvendelse derav
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK0975708T3 (da) Fremgangsmåder og materialer til nedbrydning af xanthan
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
FI20010079L (fi) Paikannusmenetelmä ja radiojärjestelmä
FI990965A7 (fi) Menetelmä kanavaestimaatin muodostamiseksi ja vastaanotin
DK199900234U4 (da) Paroxetin-methansulfonat i krystallinsk form, farmaceutisk præparat indeholdende dette og andvendelse af forbindelsen til f
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
ATE220304T1 (de) Servier- und transportaufnahme
NO20023815D0 (no) Publikumsmålingssystem og fremgangsmåte for digital kringkasting
DK1112003T3 (da) Ny sammensætning og anvendelse
NO980890D0 (no) Kontroll av trafikk og transport
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
DK1216046T3 (da) Hidtil ukendt kombination af loteprednol og antihistaminer
DK0991415T3 (da) Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
DK1092079T3 (da) Metode til fremstilling af en gassammensætning og anvendelse deraf
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK1131083T3 (da) Anvendelse af væksthormonfrigørende forbindelser og antagonister deraf til behandling af tumorer
NO995073L (no) Fjærnaktivert og låst muffeklemme
DK0905128T3 (da) Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater
NO20005763L (no) DHEA-sammensetning og fremgangsmåte